scholarly journals Finite-population evolution with rare mutations in asymmetric games

2016 ◽  
Vol 162 ◽  
pp. 93-113 ◽  
Author(s):  
Carl Veller ◽  
Laura K. Hayward
Keyword(s):  
Finite Population ◽  
Population Evolution ◽  
Rare Mutations

Investigation of Accuracy of a Calibrated Estimator of a Ratio by Modelling

2005 ◽  
Vol 10 (4) ◽  
pp. 333-342
Author(s):  
V. Chadyšas ◽  
D. Krapavickaitė
Keyword(s):  
Mean Square Error ◽  
Taylor Series ◽  
Random Sampling ◽  
Finite Population ◽  
Taylor Series Expansion ◽  
Simple Random Sampling ◽  
Population Parameter ◽  
Mean Square ◽  
Parameter Ratio ◽  
Using Data

Estimator of finite population parameter – ratio of totals of two variables – is investigated by modelling in the case of simple random sampling. Traditional estimator of the ratio is compared with the calibrated estimator of the ratio introduced by Plikusas [1]. The Taylor series expansion of the estimators are used for the expressions of approximate biases and approximate variances [2]. Some estimator of bias is introduced in this paper. Using data of artificial population the accuracy of two estimators of the ratio is compared by modelling. Dependence of the estimates of mean square error of the estimators of the ratio on the correlation coefficient of variables which are used in the numerator and denominator, is also shown in the modelling.

PREDICTIVE VALUE OF THE DYNAMIC DETERMINATION OF CIRCULATING TUMOR DNA ON PFS IN PATIENTS WITH EGFR MUTATED NSCLC, WITH OSIMERTINIB THERAPY

2020 ◽  
Vol 66 (2) ◽  
pp. 135-142
Author(s):  
Fedor Moiseenko ◽  
Mariya Stepanova ◽  
Nikita Volkov ◽  
Albina Zhabina ◽  
A. Myslik ◽  
...  
Keyword(s):  
Predictive Value ◽  
Molecular Genetic ◽  
Predictive Marker ◽  
Circulating Tumor Dna ◽  
Qualitative Assessment ◽  
Genetic Profile ◽  
T790m Mutation ◽  
Rare Mutations ◽  
Effect Of Therapy ◽  
Pcr Method

Aim: study of the predictive value of determining ctDNA during treatment with osimertinib in patients with NSCLC with EGFR mutation. Methods: The study included patients with metastatic EG-FR-associated NSCLC, in whom, with progression against the background of 1st - 2nd generation TKIs, the T790M mutation was detected. Patients received osimertinib therapy 80 mg/ day, daily, until progression. Before treatment, and then every 2 months, whole blood was taken to conduct a qualitative assessment of ctDNA in dynamics by the RT-PCR method. Results: From 2016 to 2019 in St. Petersburg Clinical Scientific and Practical Center of Specialized Types of Medical Care (Oncology), 22 patients were identified T790M associated progression of EGFR NSCLC. 81.9% (18/22) are women, 18.1% (4/22) are men. The average age is 61.2 years (50-75). 1/22 had smoking experience for more than 30 years. The molecular genetic profile in 16 is represented by ex19del, 5 L858R, 1 -a combination of rare mutations G719S+S768I. The effect of therapy was evaluated in 20/22 patients. PR and SD were registered in 9/20 (45%) and 10/20 (50%) patients, respectively. Median PFS - 16.7 months (cI 95%, 11,4-22,0). In 12/22 patients was observed the disappearance of ctDNA T790M after 2 months of osimertinib therapy. PFS is 18,9 months (95% CI, 14,8-19,7), in patients with no mutation detected in the second month of treatment compared with the group of patients in which the ctDNA was determined (PFS 8.0 months) (CI 95%, 4,2-11,8) (p=0.015). Correlation analysis did not reveal any clinical factors associated with the disappearance of ctDNA. Conclusions: The disappearance of ctDNA in plasma after 2 months of treatment with osimertinib is associated with an increase in PFS and can be considered as a predictive marker in patients with metastatic NSCLC EGFR T790M.

Sign in / Sign up

Export Citation Format

Share Document